17th New York Health Forum
September 16, 2021 (Thursday)
11:00 AM – 12:15 PM ET
*The 17th forum will be held virtually.
(Detailed information will be updated www.nyhealthforum.net)
A new class of digital therapeutics is advancing beyond prior generations’ focus on tracking adherence and digitizing behavioral therapy. It is now advancing towards the first-ever class of digital treatments that engage targets of disease to positively alter the course of treatment via drug-like mechanisms of action. Among these new therapeutic interventions are emerging treatments that leverage translational medicine and validated biomarkers to affect disease modification of chronic and debilitating conditions.
These next-generation digital therapeutics can demonstrate their potential via translationally validated mechanisms of action that positively change both structure and function in high impact, unmet needs including Alzheimer’s, Multiple Sclerosis, stroke recovery, and cognition. Given the capacity of these therapeutics to delay or change the trajectory of disease progression, a new emerging class of digital treatments emphasize the significant value for health plans, patients, and providers.
